2882-LB: MiniMed 780G Delivers Morning Euglycemia Regardless of Bedtime Glucose Levels

Introduction and Objective: Awakening with normoglycemia for people with type 1 diabetes (PwT1D) is important for short-term and long-term health. However, consistently achieving this is difficult because overnight glucose levels are influenced by many factors. This study evaluated the MiniMed™ 780G system's ability to mitigate nocturnal hyperglycemia and optimize morning glycemia in users with sensor glucose (SG) above or within range at bedtime. Methods: CareLink data (Feb 2025-Jan 2026) from consenting global MiniMed™ 780G users were analyzed for bolus-free nights (21:00-06:00). The pre-bedtime period (PBP) was defined as 21:00-00:00 and the morning fasting period (MFP) as 06:00-09:00. Outcomes were stratified by recommended optimal settings (ROS: 100 mg/dL target, active insulin time 2h ≥95%) and PBP SG (>180 or ≤180 mg/dL). Results: Among 232,031 users with PBP SG>180 mg/dL, SG fell from 212.9 to 131.7 mg/dL during MFP, with TIR rising from 21.3% to 90.3%. Among 334,931 users with PBP SG≤180 mg/dL, TIR increased from 85.1% to 93.9%, with mean SG decreasing from 139.2 to 121.3 mg/dL. ROS users achieved the highest MFP TIR (92.5% and 95.2%, for SG>180 and SG ≤180mg/dL respectively). Hypoglycemia remained minimal (<1%) across all groups. Conclusion: The MiniMed™ 780G delivered morning euglycemia regardless of hyperglycemia before bed. These outcomes were demonstrated in all users, with the greatest benefits seen in those using ROS Disclosure M. Castro: Employee; Current; Medtronic. M. Liu: Employee; Current; Medtronic. C. Rodriguez: Employee; Current; Medtronic. J. McVean: Employee; Current; Medtronic.